Oncology

I went into cancer care and cancer research because, when I was a fellow, it was the medical specialty with the largest number of challenges…

Early clinical results reveal that the novel KRAS G12D inhibitor GFH375 achieves a 41% response rate and 97% disease control in advanced…

The DESTINY-Breast11 phase 3 trial presented at ESMO 2025 revealed that the anthracycline-free neoadjuvant T-DXd-THP regimen achieved a 67.3% pathologic complete response rate.